IRCT20210306050600N1 IRCT 2021-03-26 Mashhad University of Medical Sciences Brachytherapy with concurrent Capecitabine in advanced cervical cancer Evaluation of addition of concurrent Capecitabine to brachytherapy in patients with advanced cervical cancer 2021-03-30 anticipated 35 Complete https://irct.ir/trial/54921 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Other, Purpose: Treatment, Other design features: Patient who are recruited into the trial, will be placed in the intervention arm. Control group will be matched patients who have not received concomitant chemotherapy with brachytherapy, either have not entered the trial or those previously treated. 2 Cervical cancer, FIGO stage IB-IVA. Intervention 1: Intervention group: patients who are eligible to enter the trial, are put on Capecitabine 825mg/m2 twice daily during their brachytherapy treatment, starting from the first fraction of their brachytherapy treatment till the last fraction, which can take between 10-14 days. Capecitabine is an oral chemotherapy drug, which can also increase the sensitivity of cells to radiation. In this study, capecitabine-ACTE will be used. Intervention 2: Control group: patients who have received the current standard treatment, that is brachytherapy done without concurrent chemotherapy, are compared with intervention group after they are matched based on variables like stage of disease, comorbidities and performance status. This group can be chosen from the patients who have not entered the trial, or patients who have received the standard treatment in the past. Yes - There is a plan to make this available What will be shared: De-identified demographic information and data about the primary outcome measures will be shared When: starting 6 months after the publication To whom: data will only be available to people working in academic institutions Conditions: data will only be available for research oriented prurposes Where to obtain: In order to access the data, applicant should send an email requesting access, to Dr Soudeh Arastouei(arastoueis971@mums.ac.ir) How to obtain: After receiving the email, communication will be done with the ethic committee of Mashad university of medical sciences for further authorization Comments: